Advancing Personalized Care for Neurogenic Bladder What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD: Pro Anticholinergic
Neurourology and Urodynamics · 2026
DOI: 10.1002/nau.70177 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, 2026. Verfasst von Aalya Hamouda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Urology, McGill University, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: Cholinergic Antagonists, Urinary Bladder, Neurogenic, Lower Urinary Tract Symptoms, Urinary Bladder. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Aims
To discuss the benefits and considerations of anticholinergic therapy as first‐line treatment for bladder storage symptoms in patients with neurogenic lower urinary tract dysfunction (NLUTD), integrating evidence‐based data and clinical experience.
Methods
A narrative review of international guideline recommendations, available clinical evidence, and professional experience was undertaken to evaluate the role of anticholinergics in managing disorders of bladder storage, such as neurogenic detrusor overactivity (NDO) and intrinsic sphincter dyssynergia (NISD), in patients with NLUTD.
Results
Evidence from published studies and guideline statements supports anticholinergics as effective agents for improving lower urinary tract symptoms (LUTS), detrusor overactivity (DO), and overall bladder function in patients with NLUTD. Their use has also been associated with prevention of secondary urinary complications.
Conclusions
Anticholinergics remain recommended first‐line therapy for bladder storage dysfunction in NLUTD. Clinical use should be guided by individual patient characteristics, balancing efficacy in symptom control with potential side effects and long‐term safety considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Urology, McGill University, Montreal, Québec, Canada.
- Lady Davis Research Institute, McGill University, Montreal, Québec, Canada.
ORCID-Profile: Aalya Hamouda, Claudia Covarrubias
Zitieren
APA
Hamouda, A., Covarrubias, C., & Campeau, L. (2026). Advancing Personalized Care for Neurogenic Bladder What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD: Pro Anticholinergic. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70177
Vancouver
Hamouda A, Covarrubias C, Campeau L. Advancing Personalized Care for Neurogenic Bladder What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD: Pro Anticholinergic. Neurourology and Urodynamics. 2026. doi:10.1002/nau.70177
BibTeX
@article{Hamouda2026,
author = {Hamouda, Aalya and Covarrubias, Claudia and Campeau, Lysanne},
title = {Advancing Personalized Care for Neurogenic Bladder What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD: Pro Anticholinergic},
journal = {Neurourology and Urodynamics},
year = {2026},
doi = {10.1002/nau.70177}
}
EUVIMED